Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 845 results for "novartis ag"

Novartis apologizes for not disclosing side-effects of leukemia drugs sooner

Novartis AG (NVS) Showing Support Near $93.18

The patented algorithms that power's Artificial Intelligence Center found a trading opportunity with Novartis AG ("NVS) that should provide a 2.60% return in just 124 ..., 16 hours ago

27 images for novartis ag, 2 weeks ago, 13 hours ago
4 Traders, 4 days ago
I Stock Analyst, 1 week ago
Motley Fool, 1 week ago
ABC News 4 Charleston, 2 days ago
Sys-Con Media, 2 days ago
Malay Mail, 1 month ago
Business Recorder, 3 weeks ago
4 Traders, 1 month ago

Battle Between Roche's Avastin And Novartis Lucentis Heats Up

Various studies have revealed that the use of Avastin for wet AMD does not pose serious risks or side effects. This runs contrary to Roche and Novartis claims that rendered the drug unsafe for treatment Page 1 of 2 Published: September 15, ...
 Bidness Etc19 hours ago
Motley Fool

How Much Is Novartis's New Heart Failure Medicine Worth?

Summary Novartis's investigational heart failure medicine has been found to be superior to current standard of care. LCZ696 has the potential to be a blockbuster drug. Based on my assumptions, the drug is worth around $5.5 billion or $2.20 per ...
 Seeking Alpha4 days ago This New Novartis AG Drug May Revolutionize Heart Failure Treatment  Motley Fool1 week ago BUZZ-Novartis AG: Big potential for heart failure drug  Reuters1 week ago Novartis AG's New Heart Drug Cuts Cardiovascular Death Risk By 20 Percent; "Most Exciting Ever" Med Points To Huge Sales  BioSpace1 week ago
Bidness Etc

Novartis drags DRL to US court for patent violation

Switzerland-based Novartis AG and Novartis Pharmaceuticals Corporation (NPC) have sued Dr Reddy's Laboratories in a the United States' District Court for the District of Delaware for a patent infringement action on the drug Gleevec. The action ...
 Financial Express1 week ago Novartis Wins The Battle Over Bronchodilators Against GSK  Bidness Etc1 week ago NOVARTIS : Drags drl to us court for patent violation  4 Traders4 days ago Novartis Drags DRL to US Court Over Patent Infringement  New Indian Express1 week ago

Novartis Bringing Forth A New Breakthrough Drug

Summary The new cardiovascular drug by Novartis indicated a 16% improvement in the survival rate compared to the generic drug's performance. The drug testing also indicated a 21% reduced risk of hospitalization compared to the generic rival. ...
 Seeking Alpha1 week ago Novartis Is Expanding Its Portfolio Effectively  Seeking Alpha1 week ago Ranbaxy up; nod to generic version of Novartis drug  Sify2 months ago India's Ranbaxy gains; U.S. drug regulator approves generic version of Novartis drug  Reuters2 months ago

Potential Novartis AG (NVS) Trade Has 4.03% Downside Protection

Novartis AG ("NVS) traded between $93.99 and $94.45 before closing at $94.36 Thursday and presents some attractive trading opportunities today. MarketIntelligenceCenter.comaEUR(TM)s patented ...
 Individual.com3 days ago

NOVARTIS : demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA

Novartis International AG / Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA . Processed and transmitted by NASDAQ OMX Corporate Solutions . The issuer is solely responsible for the content of ...
 4 Traders3 days ago New data confirm high efficacy of Gilenya┬« in achieving 'no evidence of disease activity (NEDA)' based on four key measures of MS  EuroInvestor4 days ago Novartis demonstrates leadership in ophthalmology with new products and over 40 abstracts at EURETINA  AndhraNews.net1 day ago Novartis: Rate Of Brain Shrinkage Faster In MS Patients - Quick Facts  RTTNews.com6 days ago

Novartis signs licensing agreement with TB Alliance for tuberculosis treatment

Novartis AG has signed an exclusive worldwide licensing agreement with the Global Alliance for TB Drug Development, or TB Alliance, a not-for-profit organization, for compounds to combat tuberculosis, or TB, that have been discovered at the Novartis ...
 Individual.com1 week ago
Bidness Etc

Pfizer Signs Agreement To Market Novartis' Respiratory Inhalers In UK

Pfizer's UK division will distribute and market two respiratory inhalers made by Novartis, the Seebri Breezhaler and the Ultibro Breezhaler, in the UK Page 1 of 2 Click Ticker to See live coverage Pfizer Inc. ( PFE ) has entered into ...
 Bidness Etc1 week ago Pfizer Inc. Strikes Pact To Market Novartis AG's Respiratory Inhalers In The UK  BioSpace1 week ago
Money Control

Natco pharma's US partner files ANDA for Everolimus

Novartis AG sells Everolimus 0.25mg, 0.5mg, and 0.75mg Tablets under Brand name Zortress in the USA market.
 Money Control1 week ago Natco's partner Breckenridge files ANDA for Everolimus tablets  Myiris1 week ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less